Defining the structural and functional roles of mutations in gp120 associated with the emergence of HIV-1 clinical resistance to the CCR5 antagonist vicriviroc

被引：0
|
作者：
Howe, J. A. [1 ]
Murgolo, N. [1 ]
Hou, Y. [1 ]
Ba, L. [1 ]
Buontempo, P. [1 ]
Strizki, J. [1 ]
Ogert, R. [1 ]
机构：
[1] Schering Plough Res Inst, Dept Biol Res Virol, Kenilworth, NJ USA
来源：
ANTIVIRAL THERAPY | 2008年 / 13卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [11] Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
    Ogert, Robert A.
    Hou, Yan
    Ba, Lei
    Wojcik, Lisa
    Qiu, Ping
    Murgolo, Nicholas
    Duca, Jose
    Dunkle, Lisa M.
    Ralston, Robert
    Howe, John A.
    VIROLOGY, 2010, 400 (01) : 145 - 155
  • [12] Molecular Recognition of CCR5 by an HIV-1 gp120 V3 Loop
    Tamamis, Phanourios
    Floudas, Christodoulos A.
    PLOS ONE, 2014, 9 (04):
  • [13] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
    Kuemmerle, Tim
    Lehmann, Clara
    Hartmann, Pia
    Wyen, Christoph
    Faetkenheuer, Gerd
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785
  • [14] Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
    Ogert, Robert A.
    Wojcik, Lisa
    Buontempo, Catherine
    Ba, Lei
    Buontempo, Peter
    Ralston, Robert
    Strizki, Julie
    Howe, John A.
    VIROLOGY, 2008, 373 (02) : 387 - 399
  • [15] Theoretical Studies on the Interactions and Interferences of HIV-1 Glycoprotein gp120 and Its Coreceptor CCR5
    Da, Lin-tai
    Wu, Yun-Dong
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (02) : 359 - 369
  • [16] A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5
    Zhao, Q
    He, YX
    Alespeiti, G
    Debnath, AK
    VIROLOGY, 2004, 326 (02) : 299 - 309
  • [17] Mapping of vicriviroc resistance mutations in HIV-1 gp120 generated by in vitro selection of a primary HIV-1 isolate in PM-1 cells
    Ogert, R. A.
    Buontempo, C.
    Wojcik, L.
    Ba, L.
    Buontempo, P.
    Ralston, R. O.
    Strizki, J. M.
    Howe, J. A.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S14 - S14
  • [18] Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5
    Tam, Kayan
    Schultz, Megan
    Reyes-Robles, Tamara
    Vanwalscappel, Benedicte
    Horton, Joshua
    Alonzo, Francis, III
    Wu, Beili
    Landau, Nathaniel R.
    Torres, Victor J.
    MBIO, 2016, 7 (06):
  • [19] Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120
    Choe, H
    Li, WH
    Wright, PL
    Vasilieva, N
    Venturi, M
    Huang, CC
    Grundner, C
    Dorfman, T
    Zwick, MB
    Wang, LP
    Rosenberg, ES
    Kwong, PD
    Burton, DR
    Robinson, JE
    Sodroski, JG
    Farzan, M
    CELL, 2003, 114 (02) : 161 - 170
  • [20] Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
    Henrich, Timothy J.
    Tsibris, Athe M. N.
    Lewine, Nicolas R. P.
    Konstantinidis, Ioannis
    Leopold, Kay E.
    Sagar, Manish
    Kuritzkes, Daniel R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (04) : 420 - 427
12345